Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | BIRB 0796 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |